# Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

> **NCT00804128** · — · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 76 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Magnetic Resonance Imaging (MRI)
- **DRUG:** Gadavist

## Key facts

- **NCT ID:** NCT00804128
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-01
- **Primary completion:** 2024-01-05
- **Final completion:** 2024-01-05
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2024-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00804128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00804128, "Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00804128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*